Page last updated: 2024-12-05

u 99194

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID5626
CHEMBL ID16410
CHEBI ID93232
SCHEMBL ID2640137
MeSH IDM0228880

Synonyms (43)

Synonym
BRD-K70281171-001-01-7
LOPAC0_001207
NCGC00025123-01
lopac-u-116
tocris-1357
NCGC00016073-01 ,
BIOMOL-NT_000031
NCGC00025123-03
u-99194
u 99194
BPBIO1_001223
NCGC00025123-02
NCGC00016073-05
L000612
CHEMBL16410 ,
(5,6-dimethoxy-indan-2-yl)-dipropyl-amine
bdbm50107876
5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine
CCG-205281
NCGC00016073-02
NCGC00016073-03
NCGC00016073-04
82668-33-5
929J96FO8T ,
pnu-99194a free base
jpc-211
1h-inden-2-amine, 2,3-dihydro-5,6-dimethoxy-n,n-dipropyl-
jpc 211
2-di-n-propylamino-5,6-dimethoxyindane
unii-929j96fo8t
SCHEMBL2640137
2,3-dihydro-5,6-dimethoxy-n,n-dipropyl-1h-inden-2-amine
DTXSID50274471
CHEBI:93232
5,6-dimethoxy-2-(di-n-propylamino) indan
FT-0738652
tam-67
Q7119895
BRD-K70281171-103-01-1
SDCCGSBI-0051174.P002
NCGC00016073-09
1h-inden-2-amine,2,3-dihydro-5,6-dimethoxy-n,n-dipropyl-
AKOS040748642
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID2517
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.40070.100020.879379.4328AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency23.71500.000811.382244.6684AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
arylsulfatase AHomo sapiens (human)Potency0.08491.069113.955137.9330AID720538
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency25.11890.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency6.74560.134610.395030.1313AID1347049
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.70790.039816.784239.8107AID1454
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency1.88540.00106.000935.4813AID943; AID944
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency12.58931.000010.475628.1838AID1457
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.84920.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.03100.00010.25675.8000AID65611
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.03100.00030.37088.1600AID65611
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.99200.00000.437510.0000AID65244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID197251In vitro stability in rat hepatocytes relative to that of PNU-93385.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID174841Inhibition of (+)-MK-801-induced hyperactivity in rats following 200 umol/kg i.p.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID174839Inhibition of (+)-MK-801-induced hyperactivity in rats following 10 uM/kg i.p.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID174842Inhibition of (+)-MK-801-induced hyperactivity in rats following 30 umol/kg i.p.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID231639Binding affinity ratio of D2/D32001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID65244Affinity at D2 dopamine receptor on CHO cell membranes by [3H]PNU-86170 displacement.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID65611Affinity at rat D3 dopamine receptor on CHO cell membranes by [3H]spiperone displacement.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID174840Inhibition of (+)-MK-801-induced hyperactivity in rats following 100 umol/kg i.p.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's5 (41.67)24.3611
2020's5 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]